Click here to watch now. It's over.
To read Elias Zerhouni's statement click here.
A pretty good presentation. Zerhouni was joined by some department heads (including our own, Joan Brugge).
Some highlights:
-The approval rate of first time RO1s by first time investigators is down from 15% in the mid 90s to 5%.
-Students are not entering science as they see a lack of opportunity.
-Investigators are spending more and more time writing grants and less time performing research and mentoring.
-High risk, high impact science is suffering the most. When budgets get tight, risky projects don't make the cut.
Too bad Arlen Specter (the Republican Senator and joint-chair of the panel) wasn't around.
- Log in to post comments
More like this
by revere, cross-posted at Effect Measure
Like a lot of other research scientists supported by NIH I got an email yesterday from NIH Director Elias Zerhouni announcing his intention to leave his position "to devote much of my attention to writing." At least it wasn't the hackneyed "to spend more…
Like a lot of other research scientists supported by NIH I got an email yesterday from NIH Director Elias Zerhouni announcing his intention to leave his position "to devote much of my attention to writing." At least it wasn't the hackneyed "to spend more time with my family." While Zerhouni won't…
At the Society for Neuroscience meeting last month, there was a special symposium regarding the current NIH funding situation that was supposed to be given by the current director of the NIH, Dr. Elias A. Zerhouni. Due to his plane being delayed, he was a no-show, although the talk was instead…
A couple of weeks ago, NEWSWEEK science columnist Sharon Begley wrote an article entitled From Bench To Bedside: Academia slows the search for cures. It was a rather poorly argued bit of polemic, backed up only with anecdotes that came across as sour grapes by scientists whose grant proposals the…